JA
EGRX

JOYN Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

JOYN Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3
Closed – – 1894
2018
Q3 		$0 Sell
3
-146
-98% -$11.1K ﹤0.01% 1912
2018
Q2 		$11K Sell
149
-334
-69% -$21K ﹤0.01% 888
2018
Q1 		$25K Buy
+483
New +$28.1K 0.01% 622

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JOYN Advisors's EGRX Position: Q4 2018 in Review

JOYN Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2018, closing a stake of 3 shares.

JOYN Advisors first reported a position in EGRX in Q1 2018 and held it in 3 quarters. The position peaked at $25K in Q1 2018. 182 funds tracked by Wall St. Rank hold EGRX as of Q4 2018.

  • JOYN Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • JOYN Advisors sold 3 Eagle Pharmaceuticals, Inc. shares in Q4 2018.
  • JOYN Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
  • JOYN Advisors's Eagle Pharmaceuticals, Inc. position peaked at $25K in Q1 2018.
  • 182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2018.

Based on JOYN Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.